IP Library Granted Patent US 8,901,113
Granted Patent B2
US 8,901,113 · App. 12/893,607 · Granted Dec 2, 2014

Methods and compositions for deterring abuse

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,901,113
App. No.
12/893,607
Granted
Dec 2, 2014
Kind
B2
Abstract

Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse comprising at least 10% by weight hydroxypropylcellulose; polyethylene oxide; and a disintegrant selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium; wherein the ratio of hydroxypropylcellulose to polyethylene oxide on a weight basis is between about 10:1 and 1:10.

Claims (12)

1. A composition suitable for reducing the chemical conversion of precursor compounds included in the composition to a drug susceptible to abuse comprising:

pseudoephedrine, or a therapeutically acceptable salt thereof;

at least 10% by weight hydroxypropylcellulose;

polyethylene oxide; and

about 2% by weight to about 25% by weight of a disintegrant selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium;

wherein the ratio of hydroxypropylcellulose to polyethylene oxide on a weight basis is between about 10:1 and 1:10.

2. The therapeutic composition of claim 1 , wherein the composition further comprises ethylcellulose.

3. The therapeutic composition of claim 2 , wherein the ethylcellulose includes ethoxyl in an amount of about 48.0% to about 49.5%.

4. The therapeutic composition of claim 2 , wherein the ethylcellulose includes ethoxyl in an amount of about 49.6% to about 52.5%.

5. The therapeutic composition of claim 2 , wherein the ethylcellulose includes ethoxyl in an amount of about 45.0% to about 47.9%.

6. The composition of claim 1 , wherein the hydroxypropylcellulose has a viscosity of about 1,500 mPa·s to about 3,000 mPa·s.

7. The composition of claim 1 , wherein the composition is an immediate release composition.

Assignments (4)
SECURITY INTEREST Recorded Jul 2, 2019
From: ACURA PHARMACEUTICALS, INC.
To: SCHUTTE, JOHN
Reel/Frame 049649/0950 →
SECURITY INTEREST Recorded Jul 2, 2019
From: SCHUTTE, JOHN
To: ABUSE DETERRENT PHARMACEUTICALS, LLC
Reel/Frame 049650/0104 →
RELEASE OF SECURITY INTEREST Recorded Oct 11, 2018
From: OXFORD FINANCE LLC
To: ACURA PHARMACEUTICALS, INC.; ACURA PHARMACEUTICALS TECHNOLOGIES, INC.
Reel/Frame 047140/0800 →
SECURITY INTEREST Recorded Mar 17, 2017
From: ACURA PHARMACEUTICALS, INC.; ACURA PHARMACEUTICAL TECHNOLOGIES, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 041623/0740 →